American Urological Association

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Retrieved on: 
Dienstag, April 16, 2024
Science, Biotechnology, Research, Oncology, Public Relations, Investor Relations, General Health, Health, Communications, American Urological Association, Abstract, Biology, Prostate, Patient, Urology, AUA, GRID

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio.
  • Studies to be presented include those that evaluate the clinical utility of the company’s Decipher tests in guiding treatment decisions for patients with prostate or bladder cancer.
  • Other presentations will explore new insights into these cancers’ underlying biology, which researchers derived through use of Veracyte’s whole-transcriptome-based Decipher GRID research tool.
  • “The data being presented at AUA 2024 expands the extensive clinical evidence supporting our Decipher Prostate and Decipher Bladder tests,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.

Recurrence Data for Narrow Band Imaging™ (NBI™) Technology Show Value in the Fight Against Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Mittwoch, April 24, 2024
MIBC, Physician, University, Cancer, Urology, Eastern Virginia Medical School, Meta-analysis, Cystoscopy, Google Images, Risk, American Urological Association, Recurrence, American Cancer Society, NBI, AIST, Patient, Classification, Eye, Systematic, NMIBC, AUA, Diagnosis, Narrow-band imaging, Neoplasm, Associate, Bladder cancer, Vesica, Medical imaging

CENTER VALLEY, Pa., April 24, 2024 /PRNewswire/ -- Olympus, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced today data showing that the use of Narrow Band Imaging (NBI) technology with patients with non-muscle invasive bladder cancer (NMIBC) led to 37% less likelihood of recurrence over 12-35 months.1 

Key Points: 
  • As reported by the American Cancer Society, bladder cancer has one of the highest recurrence rates.2 Additionally, "recurrence and progression to muscle-invasive bladder cancer (MIBC) is highly variable, depending on tumor classification and grade at diagnosis.
  • For example, in patients diagnosed with low-grade noninvasive urothelial carcinoma (Ta), recurrence rates range from 30% to 60% at 5 years; however, the risk of progression to MIBC is ≤5%.
  • In contrast, patients with high-grade urothelial carcinoma invading into the lamina propria (T1) have progression rates of 30% to 70%."
  • NBI technology will also be available for demo at the Olympus booth at the American Urological Association (AUA) conference, May 3-6, 2024, in San Antonio, TX.

Urology Care Foundation Announces 2024 Research Awards of Distinction

Retrieved on: 
Donnerstag, April 4, 2024
Western University, Research, American Urological Association, Xenobiotic, Translational research, Postdoctoral researcher, Prostate cancer, Environment, Lawson Health Research Institute, Immunology, Committee, Gut microbiota, University, Macrophage, Doctor of Philosophy, Role, Publication, Pediatrics, University of California, Pediatric urology, Division, FACS, Radiation therapy, Society, Michigan Medicine, Nursing

BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.

Key Points: 
  • BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.
  • "We are optimistic about the future of urologic research with the selection of the recipients of this year’s Urology Care Foundation Research Awards,” said Harris M. Nagler, MD, Urology Care Foundation President.
  • “We are thrilled with the Urology Care Foundation Research Awards of Distinction awardees this year,” said Steven Kaplan, MD, Chair of the AUA’s Research Council.
  • The awardees will be celebrated at the Urology Care Foundation Research Honors Program held at the AUA Annual Meeting in May 2024.

Don’t Drop the Ball! The Urology Care Foundation Urges Men to Check Themselves for Testicular Cancer Awareness Month

Retrieved on: 
Montag, April 1, 2024
Diagnosis, Health, American Urological Association, Breast, Risk, Testicular cancer, GCNIS, Medical college, Groin, Ache, Cancer, Epididymis, Scrotum, Male, Testicle, Thumb, Pain, AUA, Swelling, Courage, Birth control

BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- April is Testicular Cancer Awareness Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is urging men not to drop the ball when it comes to their testicular health.

Key Points: 
  • BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- April is Testicular Cancer Awareness Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is urging men not to drop the ball when it comes to their testicular health.
  • Testicular cancer is one of the less common cancers in men, with only 1 out of every 250 men getting diagnosed during their lifetime.
  • The best way to increase the chances we can cure someone of testicular cancer is to catch it early.
  • Prostate exams, scrotal exams, penis stuff, all of it,” said C. Freeman McCluskey, MD, testicular cancer survivor and urology resident at the Medical College of Georgia.

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Retrieved on: 
Donnerstag, März 28, 2024
BCG, American Urological Association, Disease, Carcinoma, Patient, Single, Mayo Clinic, Bladder cancer, University, Abstract, High Risk, Treatment, University of Texas System, AUA, Clothing

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that three abstracts highlighting cretostimogene will be presented at the American Urological Association (AUA) Annual Meeting, taking place at Henry B. González Convention Center in San Antonio, TX from May 3-6, 2024.

Key Points: 
  • IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that three abstracts highlighting cretostimogene will be presented at the American Urological Association (AUA) Annual Meeting, taking place at Henry B. González Convention Center in San Antonio, TX from May 3-6, 2024.
  • CG Oncology is exhibiting at the AUA meeting at booth #100.
  • “We are excited to share encouraging 12-month Phase 3 monotherapy results from the BOND-003 study at AUA 2024,” said Ambaw Bellete, President and Chief Operating Officer, CG Oncology.
  • “Our presence reinforces our commitment to improving outcomes for patients diagnosed with bladder cancer across the disease spectrum.”
    Details of the oral presentations are as follows:
    Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
    Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ
    Presenter: Robert Svatek, M.D., Urologic Oncologist at University of Texas Health Science Center, San Antonio, TX
    BOND-003- Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ

enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development

Retrieved on: 
Dienstag, April 9, 2024
NMIBC, BCG, American Urological Association, Master, Professor, Advisory Council, Patient, SVP, Thesis, University, Drug, Society, American College, LEGEND, Bladder cancer, Hofstra University, FACS, Stanford University, AUA, Prostate, Medicine, Pharmaceutical industry

In this role, Dr. Pruthi's responsibilities will include supporting the clinical development of EG-70 across the urologic space, including through engagement with the urological community.

Key Points: 
  • In this role, Dr. Pruthi's responsibilities will include supporting the clinical development of EG-70 across the urologic space, including through engagement with the urological community.
  • He joins enGene from Johnson & Johnson Innovative Medicine, where he was most recently the Global Medical Affairs Leader, Bladder Cancer and Senior Medical Director, Oncology (Global – Prostate and Bladder Cancer).
  • "We are thrilled to welcome Dr. Raj Pruthi to the enGene team.
  • In addition to his position at enGene, Dr. Pruthi maintains multiple prominent leadership roles within the urological community.

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Retrieved on: 
Montag, April 1, 2024
Technology, Health, Other Health, Radiology, Oncology, Other Technology, Practice Management, Medical Devices, Software, Managed Care, General Health, Health Technology, Hardware, Data Management, Neurology, Automation, Diagnosis, Cardiology, Molecular imaging, American Urological Association, MRI, Prostate cancer, Nuclear medicine, SNMMI, Patient, PET, Radiation, Cancer, Society, Adjustment, Radiation therapy, Workflow, Radiopharmaceutical, GE HealthCare, SPECT, MIM, Brachytherapy, ASCO, European Association of Urology, Hand, Medical imaging

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

Key Points: 
  • The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.
  • "We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare.
  • “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."
  • “Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare.

Calyxo Announces FDA Clearance for New, Redesigned CVAC System

Retrieved on: 
Dienstag, März 26, 2024
FDA, General Health, Health, Medical Devices, MGH, Kidney, American Urological Association, Urology, Massachusetts General Hospital, Infection, Incidence, SURE, Patient, CVAC, Kidney stone disease, MD, Trial of the century, Dust, Karger Publishers, Vacuum, Pain, Ureteroscopy, Hospital, Medical imaging

Calyxo, Inc. , a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment.

Key Points: 
  • Calyxo, Inc. , a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment.
  • More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback.
  • Based on learnings from over two years of real-world use, Calyxo reimagined its CVAC System to further enhance the SURE procedure.
  • “CVAC” and “Calyxo” are registered trademarks of Calyxo, Inc.

Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Retrieved on: 
Freitag, März 22, 2024
Civil service commission, Metastasis, American Urological Association, Prostate cancer, Astellas Pharma, Patient, BCR, Committee, EMA, Senior, European Medicines Agency, European, MPH, Safety, European Commission, FDA, CHMP, Food, Pharmaceutical industry

TOKYO, March 22, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.1

Key Points: 
  • With approximately 9 out of 10 of these men developing metastatic disease, the need for new and effective treatment options is critical.
  • Today's positive opinion from the Committee is an important step forward for providing an additional treatment option for these patients and complements the existing efficacy and safety data supporting the use of XTANDI across the prostate cancer disease continuum.
  • Astellas is also discussing the EMBARK data with other regulatory authorities to support additional license applications for XTANDI in this indication in 2024 and beyond.
  • Astellas has already reflected the impact from this result in its financial forecast for the current fiscal year ending March 31, 2024.

CB Insights Ranks Verana Health as a Leader in EHR-based Patient Recruitment Market

Retrieved on: 
Mittwoch, März 6, 2024
SAN, Ophthalmology, Urology, Physician, Quality of life, CB Insights, EHR, CB, Neurology, ChromeOS, Health, Patient, Data analysis, Patient recruitment, Diagnosis, American Urological Association, American Academy, Pharmaceutical industry

SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data, announced that CB Insights ranked Verana Health as a Leader in the EHR-based patient recruitment market.

Key Points: 
  • SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data, announced that CB Insights ranked Verana Health as a Leader in the EHR-based patient recruitment market.
  • This market is dedicated to leveraging electronic health record (EHR) data to amplify the efficiency and effectiveness of identifying eligible patients for clinical trials.
  • “This ranking from CB Insights underscores our team’s commitment to delivering innovative solutions that can help improve patient outcomes,” said Verana Health CEO Sujay Jadhav.
  • Last year, Verana Health also launched multiple Qdata ® modules across the three therapeutic areas of ophthalmology, neurology, and urology.